Our prior research demonstrated a 20% to 25% reduction in bacterial chondronecrosis with osteomyelitis (BCO) lameness in broilers with organic Zn, Mn, and Cu (Availa^® ZMC) supplementation. Expanding on this, we investigated the optimal timing for Availa^® ZMC feeding to mitigate BCO lameness and reduce feed additive costs in the poultry industry. In this study, we compared the application of 0.15% Availa^® ZMC for 56 days, the first 28 days, and the last 28 days. The experimental design was a randomized block design involving 1560 one-day-old chicks distributed across two wire-floor pens as BCO source infection and four treatment groups with six replicates. The source of BCO infection exhibited a cumulative lameness incidence of 83%, whereas the negative control group showed a 77% cumulative incidence of lameness (p = 0.125). Administering 0.15% of Availa^® ZMC during the initial 28 d resulted in a 41.3% reduction in BCO incidence, significantly different from the supplementation during the last 28 d (p < 0.05). However, this reduction did not differ substantially (p > 0.05) from the 56d application period. Hence, administering 0.15% Availa^® ZMC during the first four weeks emerges as the optimal timing protocol, providing a defense against lameness comparable to the continuous supplementation throughout the complete production duration. Implementing this feeding approach reduces the cost of feed additive, promotes the health of skeletal bones, and effectively protects against BCO lameness in broilers, offering a valuable consideration for producers seeking optimal outcomes in the poultry industry.

Bacterial chondronecrosis with osteomyelitis (BCO) lameness is a bone disease characterized by the translocation of bacteria from the gastrointestinal tract, which colonize microfractures in broiler leg bones caused by rapid animal growth rate and weight gain, resulting in lameness. As such, BCO lameness represents a significant challenge for the poultry industry. This study aims to evaluate the effect of spraying broiler chicks on d0 at hatch with an Enterococcus faecium probiotic on the incidence of BCO-induced lameness, utilizing a Staphylococcus aureus challenge model. There were four treatments: (1) negative control (no probiotic + no challenge, NC); (2) positive control (no probiotic + challenge, PC); (3) low dosage (4.0 × 10⁸ CFU/chick + challenge, LOW); and (4) high dosage (2.0 × 10⁹ CFU/chick + challenge, HIGH). On d5, groups two through four were challenged with Staphylococcus aureus through the drinking water at a concentration of 1.0 × 10⁵ CFU/mL. Cumulative lameness incidence was determined through daily evaluations and necropsies conducted on lame birds starting from d22. Data were subjected to a binomial general regression analysis (significant p < 0.05). On d56, the PC group exhibited the highest cumulative lameness incidence (58.0%; p < 0.05), followed by LOW (36.0%), HIGH (28.7%), and NC groups (25.3%), respectively. These results suggest early probiotic application at day-of-hatch successfully reduced the incidence of lameness in challenged birds, thus contributing to understanding of efficient and sustainable broiler production.

Broiler chicken lameness caused by bacterial chondronecrosis with osteomyelitis (BCO) is presently amongst the most important economic and animal welfare issues faced by the poultry industry, and the estimated economic loss is around USD 150 million. BCO lameness is associated with multiple opportunistic bacterial pathogens inhabiting the respiratory and gastrointestinal tracts. In cases of immune deficiency resulting from stress, injury, or inflammation of the tissue, opportunistic pathogens, mainly Staphylococcus spp., can infiltrate the respiratory or gastrointestinal mucosa and migrate through the bloodstream to eventually colonize the growth plates of long bones, causing necrosis that leads to lameness. This is the first report of developing a Staphylococcus vaccine against BCO lameness disease in broiler chickens. Electron beam (eBeam) technology causes irreparable DNA damage, preventing bacterial multiplication, while keeping the epitopes of the cell membrane intact, helping the immune system generate a more effective response. Our results show a 50% reduction of lameness incidence in the eBeam-vaccinated chicken group compared to the control. Additionally, the eBeam-vaccinated chickens present higher titer of anti-Staphylococcus IgA, signifying the development of an efficient and more specific humoral immune response. Our data establish the eBeam-killed Staphylococcus vaccine as an effective approach to reducing the incidence of lameness in broiler chickens.

Bacterial chondronecrosis with osteomyelitis (BCO) lameness is a major welfare issue for broiler production worldwide affecting approximately 1.5% of broilers over 42 days old. Excessive body weight gain causes mechanical stress on long bones, leading to micro-fractures. This condition induces a bacterial infection of fractures, resulting in bone necrosis and eventual BCO lameness. Increasing gut integrity and supporting Calcium metabolism contribute to the optimal bone structure and subsequently reduce BCO lameness. Probiotics thus provide an excellent strategy for alleviating BCO due to the improvement of intestinal integrity and barrier function. Accordingly, the present study investigated the lameness reduction through the feed supplementation of a selected probiotic. Broiler chickens were assigned to three treatments, including a control litter group (FL), a PoultryStar^®Bro probiotic fed group (BRO), and a control wire-flooring group (CW) designed to induce BCO lameness. The probiotic significantly decreased lameness by 46% compared to the control group (p < 0.05). The most predominant bacteria identified from the BCO lesions were Staphylococcus cohnii and Staphylococcus lentus. Moreover, significant increments of tight junction gene expression in jejunum and ileum, plus numerical improvements of body weight gain (BW; +360 g) and feed conversion ratio (FCR; −12 pts) were observed in BRO-supplemented birds.

Bacterial chondronecrosis with osteomyelitis (BCO) is caused by several bacteria, including Salmonella, Staphylococcus spp., Escherichia coli, Enterococcus spp., and Mycoplasma spp., and BCO is a significant animal health and welfare issue in broiler production, causing 1–2% of bird condemnation at marketing age and resulting in annual losses of tens of millions of dollars. This study evaluated the efficacy of a probiotic program alone and combined with a multivalent electron beam (eBeam)-inactivated vaccine in reducing BCO lameness. The probiotic program included an Enterococcus faecium spray (E. faecium 669, at 2 × 10⁹ CFU/bird) at hatch and a triple-strain Bacillus-based product (B. subtilis 597, B. subtilis 600, and B. amyloliquefaciens 516 at 1 × 10⁹ CFU/bird/day) in drinking water from day 1 to day 56. An aerosol transmission challenge model simulated commercial bacterial exposure. Birds were divided into five groups: a positive control (PC) group (T1) and a negative control (NC) group (T2) receiving no treatment and three treatment groups receiving the probiotic program (T3), the multivalent vaccine (T4), or both the probiotic program and the multivalent vaccine (T5). Data analyzed via ANOVA (p < 0.05) showed T3, T4, and T5 had significantly lower lameness (43.7%, 40.3%, and 40.7%) than T2 (71.0%) and T1 (83.0%). T5 resulted in reductions comparable to T4, indicating no significant synergistic effect. These findings show that probiotics alone or with a vaccine effectively mitigate BCO lameness, enhance broiler welfare, and reduce economic losses.

Gram-negative bacteria like Escherichia coli have an outer membrane that contains lipopolysaccharide (LPS), which is a powerful inducer of systemic inflammation. It is often associated with gut dysbiosis, intestinal barrier dysfunction, and liver damage. Despite increasing recognition of the gut-liver axis as a critical mediator in systemic inflammation and hepatic pathology, the efficacy of nutritional strategies targeting this pathway remains inadequately defined. This study evaluated the protective effects of zinc glycine (Zn_Gly), a highly bioavailable organic zinc chelate, against LPS-induced gut barrier disruption and liver damage in meat geese. Zn_Gly supplementation @ 80mg/kg of diet significantly attenuated LPS-induced impairments in growth performance, gut morphology, intestinal permeability and liver damage. Zn_Gly reduced considerably (p < 0.01) the levels of LPS in the both liver and ceca, and significantly increased (p<0.01) the expression of tight junction proteins (ZO-1, CLDN-1), thereby mitigating LPS translocation and systemic inflammation (IL-1β, IL-18 and TNF-α) by increasing IL-10 production. Notably, Zn_Gly reversed LPS-mediated oxidative stress by enhancing hepatic antioxidant enzyme activities (SOD, CAT, GSH-Px, T-AOC; p<0.01) and reducing oxidative markers (ROS, MDA, TBARS). Crucially, Zn_Gly mitigated the adverse effects of LPS on liver health by improving ALT, AST, IgG and IgA significantly (p<0.01) leading to reduced Ishaq pathology score and disease related histological parameters. Zn_Gly also improved the hepatic liver metabolism through increasing β-oxidation. Concurrently, Zn_Gly promoted antioxidant defense mechanism NrF2 through upregulation of markers (H0-1, NQO-1 & GCLM). In terms of mechanism, these effects were brought about by blocking the NF-κB signaling pathway, which is essential for the inflammatory liver damage caused by LPS. These findings elucidate Zn_Gly as a promising nutritional modulator of the gut-liver axis, attenuating systemic inflammation and conferring protection against inflammation-induced liver damage. This underscores its therapeutic potential for improving animal health and guiding translational strategies in metabolic disorders associated with gut and hepatic dysfunction.